EUCTR2011-002057-65-DE进行中（未招募）不适用
Effect of CD08100/02 3% gel versus placebo in subjects presenting with erythematotelangiectatic rosacea over a 4 week treatment period.
Galderma R&D SNC0 个研究点开始时间: 2011年7月22日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- The subject is a male or female adult of at least 18 years old.
- •- The subject presents a moderate to severe ETR
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 25
排除标准
- •- The subject has the following forms of rosacea or rosacea like syndrome: papulopustular rosacea, rosacea conglobata or fulminans, corticosteroids-induced rosacea or isolated pustulosis of the chin, facial erythrosis of known origin other than rosacea (known carcinoid syndrome, dysthyroidism, mastocytose, serotonin syndrome, lupus erythematosis) or peri-oral dermatitis;
- •- The subject has an underlying disease, surgical or medical condition, which, in the opinion of the investigator
- •could interfere with evaluations of rosacea itself (e.g., atopic dermatitis, eczema, acne vulgaris);
- •could put the subject at risk, such as uncontrolled chronic or serious diseases which would normally prevent participation in any clinical trial (such as cancer or AIDS);
- •- The subject has a known past history of hypersensitivity to diclofenac or any of the components of the study products
研究者
相似试验
进行中（未招募）
不适用
Effect of CD08100/02 3% gel versus placebo gel in subjects presenting with papulopustular rosacea over a 6-week treatment period.Papulopustular rosaceaMedDRA version: 14.0Level: PTClassification code 10039218Term: RosaceaSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2011-002058-30-DEGalderma R&D SNC
进行中（未招募）
不适用
Effect of CD07805/47 gel in rosacea flushingEUCTR2013-005083-26-DEGalderma R&D SNC
已完成
2 期
A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL)Cutaneous T Cell LymphomaNCT03292406Galderma R&D86
已完成
不适用
euragen® gel versus placebo in the relief of neuropathic foot paiPeripheral neuropathyISRCTN37736407Origin BioMed, Inc. (Canada)60
尚未招募
3 期
Effects of topical gel Silymarin versus placebo as an adjuvant therapy on pain management in patients with painful diabetic neuropathyPainful diabetic neuropathy.Diabetes mellitus due to underlying condition with diabetic neuropathy, unspecifiedE08.40IRCT20120215009014N501Hamedan University of Medical Sciences50